Chester County News and Community Website
MALVERN, PA — Recro (Nasdaq: REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose …
Read More MALVERN, PA — Recro Pharma, Inc. (Nasdaq: REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for development, formulation, regulatory support, manufacturing and packaging of oral solid …
Read More MALVERN, PA — Recro Pharma, Inc. (Nasdaq: REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral …
Read More MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH) a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral …
Read More MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a high-performing, revenue generating contract development and manufacturing organization, announced that due to the emerging health impact of the coronavirus pandemic, the …
Read More
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a high-performing, revenue generating contract development and manufacturing organization (CDMO), recently reported financial results for the year ended December 31, 2019.
Read More MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a high-performing, revenue-generating contract development and manufacturing organization (CDMO), announced that it has completed the spin out of its Acute Care segment, Baudax Bio. Baudax …
Read More
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a pharmaceutical company with a high-performing revenue-generating contract development and manufacturing (CDMO) division, announced that the U.S. Securities and Exchange Commission (SEC) has declared effective …
Read More MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a pharmaceutical company with a high-performing, revenue-generating contract development and manufacturing (CDMO) segment and an Acute Care segment, reported financial results for the three and …
Read More
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH) announced that it will report third-quarter financial results on Friday, November 8, 2019.
Read More